Furthermore, five CpGDMs that show an average methylation difference > 10% between patients and controls mapped to four different genes: CDCP1, MIB2, TSPAN14, and HMGA2, three of which were previously described as cancer genes (Table 1). This evidence concerns the gene TSPAN14 and cancer.